Uppsala 17th December 2018


Nanexa signs additional collaboration agreements for evaluation of PharmaShell®

A Swedish biotech company has today signed an agreement with Nanexa to evaluate PharmaShell® as a drug delivery technology for a specific substance but also as a drug delivery platform for the biotech company’s development portfolio. The evaluation is regulated by a “Material Transfer and Feasibility study agreement” and starts shortly.

The evaluation work begins with in vitro studies and plans are in place to take the formulation further into preclinical animal studies. If the evaluation goes well, the results will form the basis for negotiating an extended commercial agreement regarding PharmaShell®.

In the now agreed collaboration, Nanexa receives smaller payments on delivery of in vitro results and on delivery of materials for an in vivo study. The Swedish biotech company with which Nanexa has signed an agreement also pays for the in vivo study planned within the framework of the evaluation.


Nanexa’s CEO David Westberg comments:

I am very glad that this forward-looking biotech company has chosen to evaluate Nanexa’s PharmaShell® technology as a possible platform for their drug development. I believe that the company has a very interesting development portfolio and I see that the PharmaShell® technology can fit very well into the company’s goals.

Even more gratifying is that since Friday night, we have concluded an agreement with no less than three companies to evaluate PharmaShell® (see earlier press releases during the day). I have already communicated previously that we have had a number of ongoing discussions and that now three of these are signed pretty much the same day is fantastic and a big step for Nanexa. We will enter 2019 in a whole new situation with several exciting opportunities in these partnerships with the opportunity to extend into sharp product development.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.